Drug Shortage vs Discontinuation vs Recall: GLP-1 Examples

A drug shortage means national supply can't meet demand. A discontinuation means a manufacturer is permanently stopping a product. A recall means a specific product, usually specific lots, is being pulled or corrected because something is wrong with it. They sound similar at the pharmacy counter, but each one calls for a different next step.

GLP-1 medicines have given us real examples of all three in the past few years. Here's the plain-English version of each, using FDA's own definitions.

What is a drug shortage, officially?

Under the Federal Food, Drug, and Cosmetic Act, FDA defines a shortage as "a period of time when the demand or projected demand for the drug within the United States exceeds the supply of the drug." Two details matter:

• It's national. FDA judges shortages at the US level. Its FAQ notes that when a single pharmacy is out of stock, that's usually a temporary distribution problem, not a national shortage.
• It's temporary by design. A shortage gets marked "Resolved" when FDA's Drug Shortages Staff determines that supply from at least one manufacturer covers total market demand. Some strengths or pack sizes can still be spotty after that.

FDA's FAQ says manufacturing and quality problems are the most common cause. Other causes include delays, raw-material problems and sudden spikes in demand. The last one is very familiar to anyone who tried to fill a GLP-1 prescription in 2022–2024.

GLP-1 example: tirzepatide and semaglutide. Both injections spent long stretches on FDA's shortage list during the demand surge. FDA's compounding-policy page records the endings:

• October 2, 2024: FDA determined the tirzepatide injection shortage was resolved. After litigation sent the decision back for review, FDA reaffirmed it on December 19, 2024.
• February 21, 2025: FDA determined the semaglutide injection shortage was resolved. FDA said Novo Nordisk's supply was meeting or exceeding demand, while warning that people might still see "intermittent and limited localized supply disruptions."

Notice that last phrase. "Resolved" doesn't mean every pharmacy has every strength every day.

A shortage still running: As of late October 2026, FDA's database lists liraglutide injection as "Currently in Shortage." It was first posted July 18, 2023, and Victoza pens are shown with limited availability due to a shipping delay. To check the latest status yourself, see how to check current GLP-1 shortage status.

What is a discontinuation?

A discontinuation is a business or manufacturing decision to stop making a product for good. It isn't a safety finding. Under section 506C of the FD&C Act, makers of certain important drugs must notify FDA of a permanent discontinuance, generally at least 6 months in advance, or as soon as practicable. FDA posts these notices in a separate "Discontinuations" tab and notes that the listings reflect what manufacturers report.

GLP-1 examples, both from FDA's database:

• Saxenda (liraglutide 3 mg for weight management): FDA's shortage entry lists Novo Nordisk's Saxenda pens as "available until discontinuation in January 2027," with the reason given as discontinued manufacture. Liraglutide itself isn't disappearing, though. The same entry lists generic liraglutide pens from other companies as available.
• Original Rybelsus tablets (3, 7 and 14 mg): FDA's discontinuation listing, posted June 4, 2026, gives the reason as "discontinuation of the manufacture of the drug," and says the products will be replaced by Ozempic (semaglutide) tablets.

That pattern is common. A brand or strength goes away while the active ingredient stays available in another form. That makes a discontinuation a prescription conversation, not a reason to panic-buy. If you're switching between liraglutide and semaglutide products, this comparison covers how they differ.

What is a recall, and what do Class I, II and III mean?

FDA describes recalls as "actions taken by a firm to remove a product from the market." Most are voluntary. A company can also recall at FDA's request, or under an FDA order where the law allows it. Every recall gets a class based on risk:

Recall class	FDA's meaning in plain words
Class I	Reasonable probability the product could cause serious health problems or death
Class II	May cause temporary or medically reversible health problems, or serious harm is unlikely
Class III	Not likely to cause health problems, but breaks FDA rules
Market withdrawal	A minor issue FDA wouldn't take legal action over; the firm removes or fixes it

Recalls are specific. They name products and usually lot numbers, which is why your first move is always to compare the lot on your box.

GLP-1 example: compounded vials. In an April 2026 warning letter, FDA notes that ProRx LLC, a 503B outsourcing facility, voluntarily recalled a lot of compounded tirzepatide and various lots of compounded semaglutide multidose vials on October 15, 2025, "due to a lack of sterility assurance." That recall touched specific compounded products. It didn't touch brand-name pens.

One more wrinkle: not every recall gets a press release. FDA's recalls page says plainly that "not all recalls have press releases or are posted on this page." FDA's Enforcement Reports are the fuller record. Our guide to reading an FDA safety alert walks through what each part of a notice means.

Counterfeits are a fourth thing

A counterfeit isn't a recall of a real product. It's a fake product posing as a real one. When FDA found counterfeit Ozempic in the US supply chain, it seized the fakes and published lot and label clues. Genuine Ozempic wasn't recalled. We cover those cases in counterfeit GLP-1 medicines.

Shortage vs discontinuation vs recall at a glance

	Shortage	Discontinuation	Recall
What it means	Demand > national supply	Maker stops a product for good	Specific product removed or corrected over a problem
Is it about safety?	Not usually	No, a business or manufacturing decision	Usually yes, or a quality or legal issue
How long?	Temporary until resolved	Permanent for that product	Until the affected lots are cleared
Where FDA posts it	Drug Shortages database	"Discontinuations" tab of the same database	Recalls page and Enforcement Reports
Your first question	"Is another strength or pharmacy available?"	"What replaces it, and does my prescription need to change?"	"Is my lot affected, and should I stop using it?"
Who to call	Pharmacist, then prescriber	Prescriber	Pharmacist and prescriber; follow the notice

What not to do in any of the three

Don't fill a gap with an unfamiliar online seller, split or stretch doses on your own, or switch products without your prescriber. FDA's shortage FAQ points out that it doesn't regulate the practice of medicine. Choosing an alternative treatment is your prescriber's call. If you miss doses during a supply gap, your label has specific instructions. See missed GLP-1 dose instructions and ask your prescriber before restarting.

Common questions

Is a discontinued drug the same as a recalled drug?

No. A discontinuation is a decision to stop making a product, usually for business reasons, with advance notice. A recall pulls specific products because of a defect, contamination or labeling problem.

If FDA says a shortage is "resolved," why can't my pharmacy get it?

"Resolved" means national supply from at least one manufacturer covers demand. Specific strengths, pack sizes or local pharmacies can still have gaps. FDA warned of "intermittent and limited localized supply disruptions" when it ended the semaglutide shortage.

Is Saxenda being discontinued?

FDA's shortage database lists Novo Nordisk's Saxenda pens as available until discontinuation in January 2027. Generic liraglutide pens from other manufacturers are listed as available. Ask your prescriber about next steps.

Which recall class is the most serious?

Class I. It covers products with a reasonable probability of causing serious health problems or death.